vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是DYNAVAX TECHNOLOGIES CORP的1.6倍（$151.1M vs $94.9M），DYNAVAX TECHNOLOGIES CORP同比增速更快（17.7% vs 3.6%），DYNAVAX TECHNOLOGIES CORP自由现金流更多（$32.6M vs $12.3M），过去两年DYNAVAX TECHNOLOGIES CORP的营收复合增速更高（30.6% vs 5.1%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
DVAX vs RGR — 直观对比
营收规模更大
RGR
是对方的1.6倍
$94.9M
营收增速更快
DVAX
高出14.0%
3.6%
自由现金流更多
DVAX
多$20.3M
$12.3M
两年增速更快
DVAX
近两年复合增速
5.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $151.1M |
| 净利润 | $26.9M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 22.4% | 2.3% |
| 净利率 | 28.4% | — |
| 营收同比 | 17.7% | 3.6% |
| 净利润同比 | 53.0% | — |
| 每股收益（稀释后） | $0.21 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVAXRGR
| Q4 25 | — | $151.1M | ||
| Q3 25 | $94.9M | $126.8M | ||
| Q2 25 | $95.4M | $132.5M | ||
| Q1 25 | $68.2M | $135.7M | ||
| Q4 24 | $72.0M | $145.8M | ||
| Q3 24 | $80.6M | $122.3M | ||
| Q2 24 | $73.8M | $130.8M | ||
| Q1 24 | $50.8M | $136.8M |
净利润DVAXRGR
| Q4 25 | — | — | ||
| Q3 25 | $26.9M | $1.6M | ||
| Q2 25 | $18.7M | $-17.2M | ||
| Q1 25 | $-96.1M | $7.8M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $17.6M | $4.7M | ||
| Q2 24 | $11.4M | $8.3M | ||
| Q1 24 | $-8.7M | $7.1M |
毛利率DVAXRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率DVAXRGR
| Q4 25 | — | 2.3% | ||
| Q3 25 | 22.4% | -2.7% | ||
| Q2 25 | 15.1% | -15.6% | ||
| Q1 25 | -34.7% | 6.2% | ||
| Q4 24 | -2.3% | 7.8% | ||
| Q3 24 | 12.5% | 3.1% | ||
| Q2 24 | 7.0% | 6.9% | ||
| Q1 24 | -35.0% | 5.5% |
净利率DVAXRGR
| Q4 25 | — | — | ||
| Q3 25 | 28.4% | 1.2% | ||
| Q2 25 | 19.6% | -13.0% | ||
| Q1 25 | -141.0% | 5.7% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 21.8% | 3.9% | ||
| Q2 24 | 15.4% | 6.3% | ||
| Q1 24 | -17.2% | 5.2% |
每股收益（稀释后）DVAXRGR
| Q4 25 | — | $0.22 | ||
| Q3 25 | $0.21 | $0.10 | ||
| Q2 25 | $0.14 | $-1.05 | ||
| Q1 25 | $-0.77 | $0.46 | ||
| Q4 24 | $0.07 | $0.62 | ||
| Q3 24 | $0.12 | $0.28 | ||
| Q2 24 | $0.08 | $0.47 | ||
| Q1 24 | $-0.07 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $534.1M | $283.8M |
| 总资产 | $946.5M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DVAXRGR
| Q4 25 | — | $92.5M | ||
| Q3 25 | $160.2M | $80.8M | ||
| Q2 25 | $99.1M | $101.4M | ||
| Q1 25 | $51.7M | $108.3M | ||
| Q4 24 | $95.9M | $105.5M | ||
| Q3 24 | $119.3M | $96.0M | ||
| Q2 24 | $112.5M | $105.6M | ||
| Q1 24 | $132.0M | $115.3M |
股东权益DVAXRGR
| Q4 25 | — | $283.8M | ||
| Q3 25 | $534.1M | $279.6M | ||
| Q2 25 | $494.2M | $289.3M | ||
| Q1 25 | $530.9M | $321.5M | ||
| Q4 24 | $596.8M | $319.6M | ||
| Q3 24 | $681.4M | $314.9M | ||
| Q2 24 | $642.8M | $321.5M | ||
| Q1 24 | $618.5M | $332.0M |
总资产DVAXRGR
| Q4 25 | — | $342.0M | ||
| Q3 25 | $946.5M | $342.3M | ||
| Q2 25 | $918.4M | $349.5M | ||
| Q1 25 | $945.9M | $379.0M | ||
| Q4 24 | $986.3M | $384.0M | ||
| Q3 24 | $1.1B | $373.5M | ||
| Q2 24 | $1.0B | $376.7M | ||
| Q1 24 | $986.6M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $12.3M |
| 自由现金流率自由现金流/营收 | 34.4% | 8.2% |
| 资本支出强度资本支出/营收 | 1.3% | 2.1% |
| 现金转化率经营现金流/净利润 | 1.26× | — |
| 过去12个月自由现金流最近4个季度 | $80.5M | $38.5M |
8季度趋势，按日历期对齐
经营现金流DVAXRGR
| Q4 25 | — | $15.5M | ||
| Q3 25 | $33.8M | $12.9M | ||
| Q2 25 | $23.4M | $14.7M | ||
| Q1 25 | $-19.6M | $11.1M | ||
| Q4 24 | $53.0M | $20.0M | ||
| Q3 24 | $19.5M | $9.4M | ||
| Q2 24 | $10.7M | $18.7M | ||
| Q1 24 | $-16.7M | $7.3M |
自由现金流DVAXRGR
| Q4 25 | — | $12.3M | ||
| Q3 25 | $32.6M | $7.0M | ||
| Q2 25 | $22.0M | $9.1M | ||
| Q1 25 | $-23.6M | $10.0M | ||
| Q4 24 | $49.5M | $16.4M | ||
| Q3 24 | $18.1M | $2.6M | ||
| Q2 24 | $9.9M | $10.1M | ||
| Q1 24 | $-17.4M | $5.6M |
自由现金流率DVAXRGR
| Q4 25 | — | 8.2% | ||
| Q3 25 | 34.4% | 5.5% | ||
| Q2 25 | 23.0% | 6.9% | ||
| Q1 25 | -34.6% | 7.4% | ||
| Q4 24 | 68.8% | 11.2% | ||
| Q3 24 | 22.5% | 2.1% | ||
| Q2 24 | 13.5% | 7.7% | ||
| Q1 24 | -34.3% | 4.1% |
资本支出强度DVAXRGR
| Q4 25 | — | 2.1% | ||
| Q3 25 | 1.3% | 4.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 5.8% | 0.8% | ||
| Q4 24 | 4.8% | 2.5% | ||
| Q3 24 | 1.7% | 5.5% | ||
| Q2 24 | 1.1% | 6.6% | ||
| Q1 24 | 1.5% | 1.3% |
现金转化率DVAXRGR
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | 8.15× | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | 1.98× | ||
| Q2 24 | 0.94× | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
